Given that constitutive activation of STAT3 in glioma cells has been shown to orchestrate immune evasion and exert a pivotal role in shaping tumor immune microenvironment‐promoting immunosuppression and resistance to glioma immunotherapy [44, 45], aberrations in RAN expression and other functional SNPs of RAN affecting STAT3 in glioma should be evaluated as potential biomarkers. The gene discussed is STAT3; the disease is central nervous system cancer.